INDUCTION OF TH1 AND TH2 CD4(+) T-CELL RESPONSES BY ORAL OR PARENTERAL IMMUNIZATION WITH ISCOMS

被引:77
作者
MALOY, KJ [1 ]
DONACHIE, AM [1 ]
MOWAT, AM [1 ]
机构
[1] UNIV GLASGOW, WESTERN INFIRM, DEPT IMMUNOL, GLASGOW G11 6NT, LANARK, SCOTLAND
基金
英国惠康基金;
关键词
ISCOMS; ORAL IMMUNIZATION; CD4 T CELLS; CYTOKINES;
D O I
10.1002/eji.1830251019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined the ability of oral or parenteral immunization with immune stimulating complexes containing ovalbumin (ISCOMS-OVA) to prime T cell proliferative and cytokine responses. A single subcutaneous immunization with ISCOMS-OVA primed potent antigen-specific proliferative responses in the draining popliteal lymph node, which were entirely dependent on the presence of CD4(+) T cells. CD8(+) T cells did not proliferate in vitro even in the presence of the appropriate peptide epitope and exogenous interleukin (IL)-2. Primed popliteal lymph node cells produced IL-2, IL-5 and interferon (IFN)-gamma, but not IL-4 when restimulated with OVA in vitro. Serum antigen-specific IgG1 and IgG2a antibody responses were also primed by subcutaneous immunization with ISCOMS-OVA, confirming the stimulation of both Th1 and Th2 cells in vivo. Spleen cells from subcutaneously primed mice produced a similar pattern of cytokines, indicating that disseminated priming had occurred. Oral immunization with ISCOMS-OVA also primed local antigen-specific proliferative responses in the mesenteric lymph node and primed an identical pattern of systemic cytokine responses in the spleen. The ability of ISCOMS to prime both Th1 and Th2 CD4(+) T cell responses may be central to their potent adjuvant activities and confirm the potential of ISCOMS as future oral vaccine vectors.
引用
收藏
页码:2835 / 2841
页数:7
相关论文
共 23 条
[1]   IMMUNIZATION WITH TRYPANOSOMA-CRUZI EPIMASTIGOTE ANTIGENS INCORPORATED INTO ISCOMS PROTECTS AGAINST LETHAL CHALLENGE IN MICE [J].
ARAUJO, FG ;
MOREIN, B .
INFECTION AND IMMUNITY, 1991, 59 (09) :2909-2914
[2]  
CHALLACOMBE SJ, 1987, FOOD ALLERGY INTOLER, P269
[3]   THE ISCOM STRUCTURE AS AN IMMUNE-ENHANCING MOIETY - EXPERIENCE WITH VIRAL SYSTEMS [J].
CLAASSEN, I ;
OSTERHAUS, A .
RESEARCH IN IMMUNOLOGY, 1992, 143 (05) :531-541
[4]  
ELSON CO, 1994, HDB MUCOSAL IMMUNOLO, P391
[5]   EFFECT OF ISCOMS AND THEIR ADJUVANT MOIETY (MATRIX) ON THE INITIAL PROLIFERATION AND IL-2 RESPONSES - COMPARISON OF SPLEEN-CELLS FROM MICE INOCULATED WITH ISCOMS AND-OR MATRIX [J].
FOSSUM, C ;
BERGSTROM, M ;
LOVGREN, K ;
WATSON, DL ;
MOREIN, B .
CELLULAR IMMUNOLOGY, 1990, 129 (02) :414-425
[6]  
GARSIDE P, 1995, J IMMUNOL, V154, P5649
[7]   VACCINATION OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-RESTRICTED MURINE CD8+ CYTOTOXIC LYMPHOCYTES-T TOWARDS SOLUBLE-ANTIGENS - IMMUNOSTIMULATING-OVALBUMIN COMPLEXES ENTER THE CLASS-I MHC-RESTRICTED ANTIGEN PATHWAY AND ALLOW SENSITIZATION AGAINST THE IMMUNODOMINANT PEPTIDE [J].
HEEG, K ;
KUON, W ;
WAGNER, H .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (06) :1523-1527
[9]  
MALOY KJ, 1994, IMMUNOLOGY, V81, P661
[10]   THE MUCOSAL IMMUNE-SYSTEM - FROM FUNDAMENTAL-CONCEPTS TO VACCINE DEVELOPMENT [J].
MCGHEE, JR ;
MESTECKY, J ;
DERTZBAUGH, MT ;
ELDRIDGE, JH ;
HIRASAWA, M ;
KIYONO, H .
VACCINE, 1992, 10 (02) :75-88